GuidelineArthritis & rheumatology (Hoboken, N.J.)2020
American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1.
Guideline in Arthritis & rheumatology (Hoboken, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.Annals of the rheumatic diseases · 2022Pooled it
- Compliance with existing standards: overview comparing Cochrane with non-Cochrane living systematic reviews.Systematic reviews · 2026Article
- What the SARS-CoV-2 Pandemic Has Taught Us About Immunosuppression, Vaccinations, and Immune Dysregulation: The Rheumatology Experience.Current allergy and asthma reports · 2024Review
- Early impacts of the COVID-19 pandemic on children with pediatric rheumatic diseases.European journal of rheumatology · 2022Article
- The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database.European journal of rheumatology · 2022Article
- Impact of the COVID-19 pandemic on juvenile idiopathic arthritis presentation and research recruitment: results from the CAPRI registry.Rheumatology (Oxford, England) · 2022Article
- Impact of the COVID-19 pandemic on the frequency of the pediatric rheumatic diseases.Rheumatology international · 2022Article
- Recommendations on Off-Label Drug Use in Pediatric Guidelines.Frontiers in pharmacology · 2022Article
- Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases.Pediatric rheumatology online journal · 2021Observational
- COVID-19 in Pediatrics.Rheumatic diseases clinics of North America · 2021Review
- The impact of the COVID-19 pandemic on the field of pediatric rheumatology.Current opinion in rheumatology · 2021Review
- SARS-CoV-2 infection in children with rheumatic disease: Experience of a tertiary referral center.Archives of rheumatology · 2021Article
- Outcomes of COVID-19 in a cohort of pediatric patients with rheumatic diseases.Pediatric rheumatology online journal · 2021Article
- Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists.Rheumatology international · 2021Article
- COVID-19 and Dentistry in 72 Questions: An Overview of the Literature.Journal of clinical medicine · 2021Review
- Patients with juvenile idiopathic arthritis on TNF inhibitors exposed to COVID-19 family members.Seminars in arthritis and rheumatism · 2020Article
- Article
- SARS-CoV-2 infections in children and young people.Clinical immunology (Orlando, Fla.) · 2020Review
- Pediatric inflammatory multisystem syndrome temporally associated with COVID-19: a spectrum of diseases with many names.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020Article
- The Challenge of Managing Children With Periodic Fever Syndromes in the Era of COVID-19.Frontiers in pediatrics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 2 countries.
Funding
Abstract
objectiveTo provide clinical guidance to rheumatology providers who treat children with pediatric rheumatic disease (PRD) in the context of the coronavirus disease 2019 (COVID-19) pandemic.
methodsThe task force, consisting of 7 pediatric rheumatologists, 2 pediatric infectious disease physicians, 1 adult rheumatologist, and 1 pediatric nurse practitioner, was convened on May 21, 2020. Clinical questions and subsequent guidance statements were drafted based on a review of the queries posed by the patients as well as the families and healthcare providers of children with PRD. An evidence report was generated and disseminated to task force members to assist with 3 rounds of asynchronous, anonymous voting by email using a modified Delphi approach. Voting was completed using a 9-point numeric scoring system with predefined levels of agreement (categorized as disagreement, uncertainty, or agreement, with median scores of 1-3, 4-6, and 7-9, respectively) and consensus (categorized as low, moderate, or high). To be approved as a guidance statement, median vote ratings were required to fall into the highest tertile for agreement, with either moderate or high levels of consensus.
resultsThe task force drafted 33 guidance statements, which were voted upon during the second and third rounds of voting. Of these 33 statements, all received median vote ratings within the highest tertile of agreement and were associated with either moderate consensus (n = 6) or high consensus (n = 27). Statements with similar recommendations were combined, resulting in 27 final guidance statements.
conclusionThese guidance statements have been generated based on review of the available literature, indicating that children with PRD do not appear to be at increased risk for susceptibility to SARS-CoV-2 infection. This guidance is presented as a "living document," recognizing that the literature on COVID-19 is rapidly evolving, with future updates anticipated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.